Rep. Laurel Lee Buys TuHURA Biosciences (NASDAQ:HURA) Stock

Rep. Laurel Lee Buys TuHURA Biosciences (NASDAQ:HURA) Stock

Representative Laurel Lee (R-FL) disclosed the purchase of between $50,001 and $100,000 in shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) in a filing made on August 11th, 2025. The transaction, dated July 13th, 2025, was reported as held by her spouse.

Laurel Lee's Recent Trades

• 5/8/2025: Sold $1,001-$15,000 of NVO stock
• 11/29/2024: Sold $1,001-$15,000 of WBD stock
• 11/29/2024: Sold $1,001-$15,000 of WBD stock
• 11/25/2024: Bought $1,001-$15,000 of HURA stock
• 11/8/2024: Sold $15,001-$50,000 of GEV stock
• 10/21/2024: Bought $15,001-$50,000 of PFE stock
• 10/18/2024: Exchanged $100,001-$250,000 of HURA stock
• 10/7/2024: Bought $15,001-$50,000 of AAPL stock
• 9/10/2024: Bought $50,001-$100,000 of JPM stock
• 7/31/2024: Bought $15,001-$50,000 of AAPL stock

HURA Stock Performance

Shares of HURA opened at $1.60 on Friday, down 4.88%. The 50-day moving average was $0.91 and the 200-day moving average was $2.08. The 52-week low was $0.41 and the 52-week high was $4.44.

Since the transaction date (July 13th, 2025), HURA shares have fallen 31.88%, opening at $2.29 on the transaction date. The stock rose 11.35% in the first week and rose 21.40% over two weeks, and rose 41.92% over one month.

Debt-to-equity (ttm) was 0.03, current ratio (ttm) 0.40 and quick ratio (ttm) 0.40. Market capitalization was $88.11 million, P/E (ttm) -2.70 and beta -0.31. Return on equity (ttm) was -193.06% (negative) and net profit margin (ttm) was 0.00%. Analysts' average EPS forecast for 2029 was $0.94.

Key Stories Impacting HURA

• (Positive) The U.S. FDA granted Orphan Drug Designation to TuHURA's IFx-2.0 for treatment of stage IIB–IV cutaneous melanoma (announcement Feb 2, 2026).
• (Positive) TuHURA's shares jumped sharply after the FDA orphan-designation announcement (notable intraday surge around Feb 2–3, 2026).
• (Positive) TuHURA filed an Investigational New Drug (IND) application with the FDA for TBS-2025 to be studied in combination with a menin inhibitor in mutNPM1 relapsed/refractory AML (announcement Feb 17, 2026).
• (Neutral) TuHURA announced it regained compliance with Nasdaq's $1.00 minimum bid-price requirement after shares closed ≥ $1.00 for 11 consecutive business days (Feb 26–27, 2026).
• (Neutral) TuHURA reported third-quarter 2025 financial results and provided a corporate update describing Phase‑3 enrollment progress for IFx‑2.0 (press release Nov 14, 2025).
• (Positive) TuHURA completed an acquisition/merger that added the VISTA antibody program (TBS‑2025) to its pipeline (mid‑2025).

Analyst Ratings for HURA

HC Wainwright & Co. maintained a 'Buy' rating on HURA on 2026-02-03. HC Wainwright & Co. maintained a 'Buy' rating on 2026-01-09. Maxim Group maintained a 'Buy' rating on 2025-11-14. HC Wainwright & Co. maintained a 'Buy' rating on 2025-05-16. HC Wainwright & Co. maintained a 'Buy' rating on 2025-04-03.

Presently, 5 analysts have rated HURA with a buy recommendation, 0 have issued a hold, and 0 have given a sell rating. The average rating is 'Strong Buy'.

Institutional Investors Weigh In On HURA

VANGUARD GROUP INC holds 2,319,762 shares worth $3.62 million. BLACKROCK, INC. holds 1,566,364 shares worth $2.44 million. GEODE CAPITAL MANAGEMENT, LLC holds 662,481 shares worth $1.03 million. STATE STREET CORP holds 289,133 shares worth $451,047. BANK OF NEW YORK MELLON CORP holds 210,402 shares worth $328,227. Currently, 12.74% of the stock is owned by institutional investors.

About Laurel Lee

Representative Laurel Lee is a Republican member of the U.S. House of Representatives for Florida's 15th congressional district. She has served in the House since 2023 and was born in 1974 (age 52). Her official House website is https://laurellee.house.gov.

About HURA

TuHURA Biosciences, Inc. is a Biotechnology company developing novel technologies to overcome resistance to cancer immunotherapy and is a phase‑3 registration‑stage immuno‑oncology company. The company is headquartered in Tampa, FL. James A. Bianco is listed as CEO and the company completed its IPO on 2013-02-22.